Clinical trial
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory…
NCT00019838 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019838 |
|---|---|
| Title | UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia |
| Official title | Phase I and Pharmacokinetic Study of UCN-01 and Fludarabine in Relapsed or Refractory Low-Grade Lymphoid Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug |
| Interventions | 7-hydroxystaurosporine, fludarabine phosphate |
| Start date | Jul 1, 1999 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: